- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Peptide or derivative
Comment: Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 .
|Other ligands which bind to or alter the activity of this ligand
|Key to terms and symbols
|Click column headers to sort